What's the most recent regulatory action in Macular edema due to diabetes mellitus?

Most recent: Vabysmo — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/macular-edema-due-to-diabetes-mellitus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Macular edema due to diabetes mellitus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Macular edema due to diabetes mellitus (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Macular edema due to diabetes mellitus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vabysmo	FARICIMAB	Roche		Vascular endothelial growth factor A	2022-01-01
Beovu	BROLUCIZUMAB	Novartis		Vascular endothelial growth factor A	2019-01-01
Vegf Trap	AFLIBERCEPT	Regeneron	Vascular Endothelial Growth Factor Inhibitor	Vascular endothelial growth factor A	2011-01-01
VABYSMO	FARICIMAB-SVOA	GENENTECH INC		Angiopoietin-2, Vascular endothelial growth factor A
Lucentis	Lucentis	Santen Inc.		Vascular endothelial growth factor A
Eylea	Eylea	Texas Retina Associates		Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B
Beovu	Beovu	Novartis Pharmaceuticals		Vascular endothelial growth factor A
BYOOVIZ	RANIBIZUMAB-NUNA	SAMSUNG BIOEPIS CO LTD		Vascular endothelial growth factor A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-09 — Vabysmo · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

GENENTECH INC · 1 drug in Macular edema due to diabetes mellitus
Novartis · 1 drug in Macular edema due to diabetes mellitus
Novartis Pharmaceuticals · 1 drug in Macular edema due to diabetes mellitus
Regeneron · 1 drug in Macular edema due to diabetes mellitus
Roche · 1 drug in Macular edema due to diabetes mellitus
SAMSUNG BIOEPIS CO LTD · 1 drug in Macular edema due to diabetes mellitus
Santen Inc. · 1 drug in Macular edema due to diabetes mellitus
Texas Retina Associates · 1 drug in Macular edema due to diabetes mellitus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Macular edema due to diabetes mellitus:

Cite this brief

Drug Landscape (2026). Macular edema due to diabetes mellitus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/macular-edema-due-to-diabetes-mellitus. Accessed 2026-06-10.

Macular edema due to diabetes mellitus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing